Nano cap OpGen (NASDAQ:OPGN) rallies 53% premarket on robust volume in reaction to its announcement that subsidiary Curetis GmbH has received CE Mark certification for its SARS-CoV-2 molecular test with PCR-compatible universal lysis buffer (PULB).
The test uses real-time polymerase chain reaction (RT-PCR) technology for the qualitative (yes/no answer) detection of the coronavirus in oropharyngeal and nasopharyngeal samples.
Commercial launch is underway.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.